SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Hospice and Palliative Medicine®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sood, A.
Right arrow Articles by Loprinzi, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sood, A.
Right arrow Articles by Loprinzi, C. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cancer
*Cancer Chemotherapy
*Palliative Care
Hazardous Substances DB
*METHYLPHENIDATE
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Use of methylphenidate in patients with cancer

Amit Sood, MD

Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota

Debra L. Barton, RN, PhD

Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota

Charles L. Loprinzi, MD

Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota

Cancer and its treatment are often associated with symptoms such as depression, somnolence, cognitive abnormalities, and fatigue. Methylphenidate, a stimulant medication, is commonly used to treat these symptoms. Several small pilot and a few adequately powered studies have assessed the safety and efficacy of methylphenidate in patients with cancer. Overall, the studies so far suggest that methylphenidate is well-tolerated in patients with cancer. Further, the studies have provided initial evidence of efficacy of this agent in patients with cancer. The present article reviews the evidence base behind the use of methylphenidate in these patients.

Key Words: methylphenidate • cancer • palliative care • fatigue

American Journal of Hospice and Palliative Medicine®, Vol. 23, No. 1, 35-40 (2006)
DOI: 10.1177/104990910602300106
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
J. Nikles, G. Mitchell, J. Walters, J. Hardy, P. Good, D. Rowett, T. Shelby-James, and D. Currow
Prioritising drugs for single patient (n-of-1) trials in palliative care
Palliative Medicine, October 1, 2009; 23(7): 623 - 634.
[Abstract] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
R. R. Ali, K. M. Winkfield, and A. N. Galanos
Letter to the Editor
American Journal of Hospice and Palliative Medicine, August 1, 2006; 23(4): 267 - 268.
[PDF]


Advertisement